Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus
Autore:
Treadway, JL; Mendys, P; Hoover, DJ;
Indirizzi:
Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis Biol, Groton Labs, Groton, CT 06340 USA Pfizer Global Res & Dev Groton CT USA 06340 on Labs, Groton, CT 06340 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 3, volume: 10, anno: 2001,
pagine: 439 - 454
SICI:
1354-3784(200103)10:3<439:GPIFTO>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUCOPYRANOSYLIDENE-SPIRO-THIOHYDANTOIN; ISOTOPOMER DISTRIBUTION ANALYSIS; NUCLEAR-MAGNETIC-RESONANCE; GLUCOSE ANALOG INHIBITORS; IN-VIVO; CARDIOVASCULAR-DISEASE; POTENT INHIBITOR; GLYCOSIDASE INHIBITORS; ANTIDIABETIC DRUG; GLYCEMIC CONTROL;
Keywords:
antihyperglycaemic; blood glucose; diabetic animal models; diabetic complications; drug discovery; enzyme; gluconeogenesis; glycogen phosphorylase inhibitor; glycogenolysis; hepatic glucose production; indole inhibitor site; myocardial infarction; obesity; oral hypoglycaemic agents; stroke; type 2 diabetes mellitus therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
93
Recensione:
Indirizzi per estratti:
Indirizzo: Treadway, JL Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis Biol, Groton Labs, Groton, CT 06340 USA Pfizer Global Res & Dev Groton CT USA 06340 on, CT 06340 USA
Citazione:
J.L. Treadway et al., "Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus", EXPERT OP I, 10(3), 2001, pp. 439-454

Abstract

Type 2 diabetes mellitus is a severe disease with large economic consequences. which is significantly under-diagnosed and incompletely treated in thegeneral population. Control of blood glucose levels: is 3 key objective intreating diabetic patients, who are most often prescribed one or more oralhypoglycaemic agents in addition to diet and exercise modification as wellas insulin. In spite of the availability of different classes of hypoglycaemic drugs, treatment regimens are often unable to achieve an intensive degree of glucose control known to must effectively reduce the incidence and severity of diabetic complications. Hepatic glucose output is elevated in type 2 diabetic patients and current evidence indicates that glycogenolysis (release of monomeric glucose front the glycogen polymer storage form) is animportant contributor to the;abnormally high production of glucose by the liver. Glycogen phosphorylase is the enzyme that catalyses this release andrecent advances in new. inhibitors of this structurally and kinetically well studied enzyme have enabled work which further delineate the pharmacological and physiological consequences of inhihiting glucose production by this pathway, Most notably, these agents lower glucose in diabetic animal models, both acutely and chronically, appear to affect both gluconeogenic and glycogenolytic pathways and demonstrate potential for a beneficial effect oncardiovascular risk factors. Cumulatively. this information has bolstered interest and promise in glycogen phosphorylase inhibitors (GPIs) as potential new hypoglycaemic agents fur treatment of type 2 diabetes mellitus.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:36:39